Icatibant Zentiva

Icatibant acetate, the active ingredient in Icatibant Zentiva, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It treats acute attacks of hereditary angioedema in adult patients. GNH USA supplies Icatibant Zentiva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant Zentiva is used within the hereditary angioedema therapeutic pathway to control rapid swelling episodes. - Hereditary angioedema (HAE) in adults: provides rapid reduction of edema and relief of acute attack symptoms.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: localized discomfort at the injection site. - Redness or erythema: mild skin irritation around the injection area. - Swelling at injection site: transient local edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate head pain. - Dizziness: transient sensation of light‑headedness.

Serious or Rare Side Effects: - Hypotension: significant drop in blood pressure requiring medical attention. - Anaphylaxis: severe allergic reaction with airway compromise. - Severe injection site necrosis: tissue damage at the injection site. - Thrombocytopenia: low platelet count observed in rare cases.

Before initiating therapy, clinicians should consider several safety aspects. - Hypersensitivity assessment: avoid use in patients with known allergy to icatibant or its excipients. - Airway monitoring: observe for signs of airway obstruction during acute attacks. - Concomitant bradykinin agents: evaluate potential additive effects. - Renal or hepatic impairment: use with caution as clearance data are limited. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medications that influence the bradykinin pathway or vascular tone.

Major Interactions (Avoid): - Other bradykinin B2 antagonists: concurrent use may lead to excessive blockade. - ACE inhibitors: may alter bradykinin dynamics and affect efficacy.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: can increase HAE frequency; monitor attack pattern. - Diuretics: may potentiate hypotensive effects; observe blood pressure. - Antihistamines: may mask early signs of allergic reactions; assess patient response.